Tandem Diabetes Care Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名80/208位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為23.09。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。
Tandem Diabetes Care Inc評分
相關信息
行業排名
80 / 208
全市場排名
188 / 4562
所屬行業
醫療設備與耗材
壓力支撐
由於公司未披露,未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
看空
Tandem Diabetes Care Inc亮點
亮點風險
Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.
Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.
公司代碼TNDM
公司Tandem Diabetes Care Inc
CEOSheridan (John F)
網址https://www.tandemdiabetes.com/
常見問題
Tandem Diabetes Care Inc(TNDM)的當前股價是多少?
Tandem Diabetes Care Inc(TNDM)的當前股價是 21.700。
Tandem Diabetes Care Inc 的股票代碼是什麼?
Tandem Diabetes Care Inc的股票代碼是TNDM。
Tandem Diabetes Care Inc股票的52週最高點是多少?
Tandem Diabetes Care Inc股票的52週最高點是37.930。
Tandem Diabetes Care Inc股票的52週最低點是多少?
Tandem Diabetes Care Inc股票的52週最低點是9.980。
Tandem Diabetes Care Inc的市值是多少?
Tandem Diabetes Care Inc的市值是1.47B。
Tandem Diabetes Care Inc的淨利潤是多少?
Tandem Diabetes Care Inc的淨利潤為-96.03M。
現在Tandem Diabetes Care Inc(TNDM)的股票是買入、持有還是賣出?
根據分析師評級,Tandem Diabetes Care Inc(TNDM)的總體評級為買入,目標價格為23.091。
Tandem Diabetes Care Inc(TNDM)股票的每股收益(EPS TTM)是多少
Tandem Diabetes Care Inc(TNDM)股票的每股收益(EPS TTM)是-3.030。